

# Nosocomial pneumonia - Pipeline Insight, 2021

<https://marketpublishers.com/r/N41741E8C23EEN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: N41741E8C23EEN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Nosocomial pneumonia - Pipeline Insight, 2021," report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Nosocomial pneumonia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Nosocomial pneumonia Understanding

#### Nosocomial pneumonia: Overview

Nosocomial pneumonia, also known as Hospital-acquired pneumonia (HAP) is a common nosocomial bacterial infection and is most prevalent in medical and surgical intensive care units (ICUs). It is defined as pneumonia that occurs 48 hours or more after hospital admission and not incubating at the admission time. Signs and symptoms of indication may include cough, expectoration, a rise in body temperature, chest pain, fever, tachypnea, and/or crackles. Imaging studies for the diagnosis or exclusion of Nosocomial pneumonia include chest radiographs, CT, and Chest ultrasound. Early initiation of adequate empiric antibiotic therapy for the management of Nosocomial pneumonia, is associated with improved survival compared with initial inadequate therapy.

'Nosocomial pneumonia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nosocomial pneumonia pipeline landscape is provided which includes the disease overview and Nosocomial pneumonia treatment guidelines. The assessment part of the report embraces, in depth Nosocomial pneumonia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nosocomial pneumonia R&D. The therapies under development are focused on novel approaches to treat/improve Nosocomial pneumonia.

### Nosocomial pneumonia Emerging Drugs Chapters

This segment of the Nosocomial pneumonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Nosocomial pneumonia Emerging Drugs

#### Suvratoxumab: AstraZeneca

Suvratoxumab is a human immunoglobulin G1 kappa monoclonal antibody with an extended half-life, targeted pore-forming ? toxin of *Staphylococcus aureus*. The drug is in Phase II clinical studies for the treatment of Nosocomial pneumonia.

#### Tosatoxumab: Aridis Pharmaceuticals

Tosatoxumab (AR-301, Salvecin) is an intravenous, broadly active, human monoclonal antibody (IgG1?) that targets the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin. The drug is in Phase III clinical developmental studies for the treatment of Nosocomial pneumonia.

Further product details are provided in the report..

Nosocomial pneumonia: Therapeutic Assessment

This segment of the report provides insights about the different Nosocomial pneumonia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nosocomial pneumonia

There are approx. 13+ key companies which are developing the therapies for Nosocomial pneumonia. The companies which have their Nosocomial pneumonia drug candidates in the most advanced stage, i.e. Phase III include, Aridis Pharmaceuticals.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Nosocomial pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nosocomial pneumonia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nosocomial pneumonia therapeutic

drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nosocomial pneumonia drugs.

## Nosocomial pneumonia Report Insights

Nosocomial pneumonia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Nosocomial pneumonia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Nosocomial pneumonia drugs?

How many Nosocomial pneumonia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nosocomial pneumonia?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nosocomial pneumonia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Nosocomial pneumonia and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Merck & Co

Clarametyx Biosciences

Aridis Pharmaceuticals

Clarametyx Biosciences

Nabriva Therapeutics

Hoth Therapeutics

Helperby Therapeutics

AstraZeneca

## Key Products

Tedizolid

Tosatoxumab

Panobacumab

Lefamulin

CMTX 101

AR 401

HT-006

HY-012B5

HY-015B12

Suvrattoxumab

## Contents

Introduction

Executive Summary

Nosocomial pneumonia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Nosocomial pneumonia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Nosocomial pneumonia companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Nosocomial pneumonia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Tosatoxumab: Aridis Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Suvrattoxumab: AstraZeneca

Product Description

Research and Development

Product Development Activities



Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis

Lefamulin: Nabriva Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical/Discovery Stage Products

Comparative Analysis

CMTX 101 Clarametyx Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Nosocomial pneumonia Key Companies

Nosocomial pneumonia Key Products

Nosocomial pneumonia- Unmet Needs

Nosocomial pneumonia- Market Drivers and Barriers

Nosocomial pneumonia- Future Perspectives and Conclusion

Nosocomial pneumonia Analyst Views

Nosocomial pneumonia Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Nosocomial pneumonia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Nosocomial pneumonia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Nosocomial pneumonia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/N41741E8C23EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N41741E8C23EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970